PLX
Protalix Biotherapeutics Inc
2.70$
+1.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | 100.0% | 100.0% | 100.0% | – | – | – | 100.0% | 100.0% | 100.0% | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | 78.5% | 75.5% | – | – | – | – | – | 23.3% | 23.3% | – | – | 921.4% | 39.0% | 18.2% | 23.7% | 47.1% | 59.7% | 16.7% | 91.3% | 72.3% | 27.2% | 19.9% | 17.3% | 42.6% | 41.1% | 35.1% | 45.5% | 52.2% | |
| – | – | 21.5% | 24.5% | 100.0% | – | – | – | 72.1% | 76.7% | 76.7% | – | – | -821.4% | 61.0% | 17.2% | 76.3% | 52.9% | 40.3% | 83.3% | 8.7% | 27.7% | 72.8% | 80.1% | 82.7% | 57.4% | 58.9% | 64.9% | 54.5% | 47.8% | |
| – | – | – | – | – | – | – | – | – | 2,349.3% | 3,497.3% | – | – | 5,576.8% | 266.4% | 370.2% | 83.3% | 253.8% | 180.4% | 458.9% | 330.6% | 136.8% | 97.3% | 81.6% | 60.7% | 77.5% | 61.6% | 26.1% | 24.3% | 36.1% | |
| – | – | 26.0% | 42.9% | 38,185,200.0% | – | – | – | 38.5% | 62.2% | 3,016.7% | – | – | 1,841.2% | 61.2% | 82.6% | 28.4% | 72.8% | 63.7% | 166.8% | 101.7% | 54.7% | 5.7% | 10.9% | 8.1% | 10.5% | 28.5% | 38.9% | 76.4% | 22.1% | |
| – | – | 36.1% | 47.5% | 38,185,200.0% | – | – | – | 38.5% | 62.2% | 6,514.0% | – | – | 7,418.0% | 327.5% | 452.8% | 111.7% | 295.9% | 206.5% | 625.7% | 369.2% | 191.5% | 129.2% | 99.7% | 78.4% | 110.7% | 86.2% | 48.9% | 47.1% | 58.3% | |
| – | – | -14.6% | -23.0% | -38,200,000.0% | – | – | – | -38.5% | -3,859.3% | -6,469.3% | – | – | -8,239.4% | -266.5% | -435.6% | -35.4% | -235.5% | -188.4% | -542.4% | -360.5% | -163.8% | -56.4% | -19.6% | 4.3% | -53.4% | -27.3% | 16.0% | 7.3% | -10.4% | |
| – | – | 0.6% | 0.0% | 0.0% | – | – | – | 0.0% | 0.0% | 0.0% | – | – | 136.3% | 8.6% | 0.0% | 0.1% | 5.9% | 32.6% | 85.6% | 45.6% | 46.1% | 22.4% | 14.6% | 15.4% | 19.6% | 5.3% | 4.9% | 2.0% | 2.3% | |
| – | – | – | -30.1% | -23,200,000.0% | – | – | – | -563.0% | -3,830.7% | -229.3% | – | – | 8,103.1% | 257.9% | 0.0% | -33.7% | -241.4% | -219.6% | -625.2% | -317.2% | -395.9% | -77.3% | -33.4% | -10.4% | -71.9% | -30.2% | 13.1% | 7.8% | -10.6% | |
| – | – | -0.3% | 5.1% | -12,600,000.0% | – | – | – | 37.2% | -9.4% | 7,436.0% | – | – | 16,206.2% | 433.9% | 516.4% | 0.0% | 0.0% | -19.4% | -2,006.6% | 118.0% | 37.0% | 1.6% | 14.6% | 13.3% | 16.7% | 1.1% | 0.4% | 2.3% | 1.9% | |
| – | – | -14.3% | -28.1% | -10,600,000.0% | – | – | – | -37.2% | -3,830.7% | -6,284.7% | – | – | -8,103.1% | -257.9% | -435.6% | -33.7% | -241.4% | -197.5% | 1,329.9% | -319.2% | -395.9% | -77.3% | -33.4% | -10.4% | -71.9% | -31.3% | 12.7% | 5.5% | -12.5% | |
| – | – | -12.1% | -18.4% | -38,200,000.0% | – | – | – | -38.5% | -3,652.0% | -5,994.7% | – | – | -7,726.5% | -238.6% | -392.3% | -23.0% | -204.8% | -166.4% | -485.3% | -250.0% | -340.6% | -49.9% | -15.9% | 7.1% | -49.4% | -22.6% | 19.8% | 12.2% | -5.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.